small cell lung cancer
FDA Approves Imfinzi for Limited-Stage Small Cell Lung Cancer
The FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) ...
DECEMBER 5, 2024
FDA Approves Tecentriq Hybreza for Subcutaneous Injection for All Adult Indications of IV Tecentriq
The FDA has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) for subcutaneous injection ...
SEPTEMBER 16, 2024
Consolidation Immunotherapy in Limited-Stage Small Cell Lung Cancer Improves Overall Survival
After platinum-based chemoradiotherapy, a consolidation immunotherapy regimen significantly improved overall ...
JUNE 12, 2024
FDA Grants Accelerated Approval to Imdelltra for Extensive-Stage Small Cell Lung Cancer
The FDA has granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen) for extensive-stage small cell lung ...
MAY 17, 2024
Study Defines SCLC Subtypes With Distinct Therapeutic Vulnerabilities
Countering the one-size-fits-all treatment for small-cell lung cancer, investigators classified the malignancy into ...
FEBRUARY 2, 2021
Imfinzi Approved for First-Line Treatment of Extensive-Stage SCLC
The FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or ...
APRIL 6, 2020
Keytruda Gains Approval for Treatment of SCLC
The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of patients who have ...
JUNE 20, 2019
FDA Approves Opdivo as Third-Line Rx for SCLC
The FDA granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with ...
AUGUST 21, 2018
Statins Do Not Benefit Patients With Lung Cancer
It was initially thought that lowering cholesterol levels could impair the development and growth of cancer cells, ...
FEBRUARY 28, 2017
Immune Checkpoint Inhibitors in SCLC
Antibodies targeting immune checkpoint inhibitors may be effective in improving survival outcome in patients with ...
JULY 29, 2016